Navepegritide
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Navepegritide in children with achondroplasia.
Journal: Translational pediatrics
Published: April 13, 2026
Navepegritide combined with lonapegsomatropin for the treatment of children with achondroplasia: 52-week results from the phase 2 COACH trial.
Journal: European journal of endocrinology
Published: February 06, 2026
Achondroplasia management in the era of targeted therapies: a meta-analysis of C-type natriuretic peptide analogs.
Journal: Journal of the Endocrine Society
Published: January 29, 2026
Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial.
Journal: JAMA pediatrics
Published: November 17, 2025
Assessing signs and impacts of achondroplasia: psychometric evaluation of the Achondroplasia Child Experience Measures.
Journal: Journal of patient-reported outcomes
Published: September 12, 2025
Achondroplasia treatments in children aged 5 and older.
Journal: Molecular and cellular pediatrics
Published: July 26, 2025
Progress in managing children with achondroplasia.
Journal: Expert review of endocrinology & metabolism
Published: August 12, 2024
Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial.
Journal: EClinicalMedicine
Published: July 07, 2023
Showing 1-10 of 10
Last Updated: 09/26/2026